AbCellera: Mapping the Future of Antibody Drugs.
AbCellera is currently undergoing a "maturity" phase where it is no longer just discovering antibodies for others, but advancing its own proprietary candidates.
Dear Growth Investors,
AbCellera Biologics, ticker ABCL, is a Canadian biotechnology company that operates a high-speed, AI-powered "engine" for antibody discovery. Originally known for its rapid development of COVID-19 treatments with Eli Lilly, the company has spent 2024 and 2025 pivoting from a service-based platform to a clinical-stage drug developer with its own internal pipeline.
Is the company just a "platform play", that cannot prove its AI engine can produce drugs better than conventional methods? We should take a closer look at this.
Table of Contents
Investment Thesis
TAM
Company History and IPO
The Peter Thiel Connection
CEO Carl Hansen
Company Overview and Strategy
Partnerships
Pipeline
Milestones
Platform
ABCL635 Commercial Opportunity
Internal Programs ABCL575
Royalty Portfolio and Partnered Programs
Q3 2025
Conclusion
Investment Thesis
Over a period of approximately five years, from December 2020, to January 10, 2026, the overall trend of the stock is massively negative: Since its IPO and early all-time high, the stock has suffered a dramatic decline in value. At the beginning of the period shown, at the end of 2020, the stock started at a high of almost $60, but fell rapidly during 2021. This downward trend continued through 2022 to 2024, with occasional slight recoveries repeatedly followed by new lows.
In the last twelve months of the chart, the price appears to have stabilized at a very low level between approximately $3 and $6. As of January 10, 2026, the stock is trading at $4.54.
In summary, the chart shows a negative overall change of -92.6%. This corresponds to an average future growth rate (CAGR) of -40.0%. The company has therefore rapidly lost its entire market capitalization since the end of 2020 and is currently in a prolonged bottoming-out phase.
What’s the Investment Case?
AbCellera presents an attractive investment opportunity as a clinical-stage biotech company that has successfully transitioned from a pure service provider to a developer of its own therapeutic programs. The company boasts approximately $520 million in cash, providing a solid foundation for executing its long-term strategy. The investment case rests on two pillars:
first, the potential of its internal pipeline with candidates such as ABCL635 and ABCL575, targeting multi-billion-dollar markets.
second, an extensive royalty portfolio comprising over 100 partner programs. With initial clinical data readouts expected in 2026, significant value drivers are anticipated.
TAM
The global antibody drug market is currently undergoing a massive expansion, valued at $218.6 billion in 2023 and projected to reach $412.1 billion by 2029. This growth, characterized by a CAGR of 11.2%, is primarily fueled by a surge in new product approvals and the rising prevalence of chronic conditions like cancer and autoimmune diseases. However, the sector faces headwinds from stringent price controls and the risk of adverse side effects associated with monoclonal antibody (mAb) therapies.
The market is analyzed through four primary lenses: antibody type, manufacturing process, application, and region.
By Antibody Type: The market is divided into human, humanized, chimeric, and murine antibodies.
Human antibodies currently dominate the market, holding the largest share in 2023.
This segment is expected to outpace the overall market with a CAGR of 13.4% through 2029.
By Application: Autoimmune diseases represent a significant pillar of the industry.
In 2023, this segment accounted for 39.5% of the total market.
It is forecast to grow at a CAGR of 10.6%, reaching an estimated value of $158.5 billion by the end of the decade.
By Region: North America remains the undisputed leader in the global landscape.
In 2023, the region held a 54.9% market share.
This dominance is sustained by a high concentration of major biopharmaceutical companies and a rapid pace of new clinical launches.
Company History and IPO
AbCellera was founded in 2012 as a spin-off from the University of British Columbia. Unlike traditional biotech companies that focus on developing their own drugs, AbCellera was built as a "discovery engine", a technology partner for the world’s largest pharmaceutical companies.
While the company spent years refining its microfluidic and AI stack, it achieved global fame during the COVID-19 pandemic. In 2020, AbCellera partnered with Eli Lilly to identify antibodies from a recovered patient’s blood. In a record-breaking 90 days, they moved from a blood sample to a clinical trial. This collaboration produced Bamlanivimab, the first monoclonal antibody treatment authorized by the FDA for COVID-19.
On December 11, 2020, AbCellera went public on the NASDAQ under the ticker ABCL. Shares were initially priced at $20, above the expected range and the stock surged over 250% on its first day, closing at $58.90. The company’s market cap hit $15.7 billion at the end of its first day, making it the largest IPO in Canadian biotech history. On the other hand, the IPO provided the capital to transition from a service-based model to a co-development model, where AbCellera retains ownership stakes in the drugs it helps discover.
The Peter Thiel Connection
Billionaire investor and Palantir co-founder Peter Thiel played a pivotal role in AbCellera’s transition from a quiet research firm to a Silicon Valley-style “tech-bio” powerhouse. Thiel joined AbCellera’s Board of Directors in November 2020, just weeks before the IPO. His involvement was seen as a massive vote of confidence in the company’s “Zero to One” potential, Thiel’s philosophy of investing in companies that create entirely new categories rather than incremental improvements.
Thiel served as the Chairman of the Nominating and Corporate Governance Committee. CEO Carl Hansen frequently cited Thiel’s mentorship as a key factor in scaling the company’s vision to “level the playing field” for drug innovators. After three years of service, Thiel resigned from the board on March 7, 2024. His departure was described as being for “personal reasons” and not due to any disagreements with the company. Despite his exit, his influence remains embedded in the company’s long-term, technology-first approach to biology.
CEO Carl Hansen
Dr. Carl Hansen is the founding CEO, President, and Chairman of AbCellera. Before leading the company, he was a Professor at the University of British Columbia for over a decade, where he specialized in microfluidics and genomics. Hansen is often described as an “entrepreneurial scientist.” He is the primary architect of AbCellera’s business model, which treats drug discovery like a data science problem rather than a traditional lab process. His vision is to build the “operating system” for antibody discovery.
Hansen is an inventor on over 50 US patents, reflecting his deep technical involvement in the platform’s core technology. He has stated that his goal is for AbCellera to become one of the top 10 biotech companies in the world (published by Investment Reports in January 2023) by using technology to solve “nefariously difficult” biological problems. Following the 2020 IPO, Hansen’s close to 19% stake in the company briefly made him a billionaire, symbolizing the massive value shift from traditional pharma manufacturing to AI-driven discovery.
Company Overview and Strategy
AbCellera utilizes an integrated engine that combines computer science, engineering, and biology to accelerate the discovery and development of differentiated antibody therapies. The company’s strategy is based on creating a competitive advantage through investments in technological capabilities, enabling it to solve complex medical problems and repeatedly deliver first-in-class or best-in-class medicines. In 2023, AbCellera shifted its focus from pure partnerships to prioritizing a pipeline of internally developed and co-developed programs. The goal is long-term value creation through building a portfolio of proprietary assets.
Partnerships
AbCellera’s foundation was laid over ten years through partnerships with leading pharmaceutical and biotech companies such as AbbVie, GSK, and Eli Lilly.
These collaborations served as drivers for research and development, generating short-term revenue through research grants and long-term potential through royalty payments. To date, over 100 therapy-related programs have been initiated by partners, with AbCellera often contributing leading capabilities in challenging target structures and bispecific antibodies. The company is also a key beneficiary of the Canadian government's Strategic Innovation Fund, receiving significant non-dilutive capital to build domestic biotech infrastructure.
Pipeline
AbCellera currently leads a growing internal pipeline focused on high-quality targets:
• ABCL635: An antibody in the field of endocrinology (Phase 1). Endocrinology is the branch of medicine focused on the endocrine system, a network of glands (like the thyroid, pituitary, and pancreas) that produce and secrete hormones, chemical messengers controlling vital functions like metabolism, growth, mood, and reproduction; endocrinologists diagnose and treat hormone-related disorders such as diabetes, thyroid issues, infertility, and osteoporosis.
ABCL635 is a potential first-in-class antibody medicine for the non-hormonal treatment of VMS (commonly known as hot flashes) associated with menopause.
• ABCL575: An OX40L antagonist for immunology and inflammation (Phase 1). Immunology is the study of the immune system, our body's defense network, while inflammation is a crucial, protective process orchestrated by the immune system to fight infections or injury, involving immune cells, blood vessels, and signaling molecules, though it can become harmful when chronic, leading to diseases.
ABCL575 is an investigative monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions.
• ABCL688: An autoimmune disease program currently in IND/CTA studies. IND application (Investigational New Drug) is a crucial submission to the U.S. FDA for permission to test a new drug or biologic in human clinical trials, ensuring safety with preclinical data, manufacturing details, and study plans, allowing temporary interstate shipment for research before market approval (NDA). It’s the first step for a drug sponsor to start human testing, focusing on protecting participants and gathering data for future market applications. A Clinical Trial Application (CTA) is a formal request submitted to national health authorities (like the EMA in Europe or FDA in the US, where it's called an IND) seeking authorization to conduct a clinical study with human participants, providing detailed information on the drug, study design, safety, and ethics to ensure participant well-being and scientific validity before starting human testing.
ABCL688 is a potential antibody medicine targeting a multipass complex membrane protein for the treatment of an undisclosed indication in autoimmunity
In addition, over 20 programs are in the discovery phase, approximately half of which target complex membrane proteins.
Milestones
Commencement of operations at the new clinical manufacturing facility.
Phase 1 clinical data readouts for ABCL635 and ABCL575 are expected in 2026.
The intention is to submit 1 to 3 new IND applications annually to continuously expand the clinical pipeline.
Platform
The company’s technological strength lies in specialized platforms:
• GPCR & Ion Channel Platform: This platform targets clinically validated membrane proteins that are difficult to address using traditional methods.
• T-Cell Engager Platform: Focuses on bispecific antibodies for solid tumors and autoimmunity, with the potential for improved safety and specificity. These platforms enable AbCellera to access targets in areas such as pain, fibrosis, and endocrinology that were previously considered largely inaccessible.
ABCL635 Commercial Opportunity
ABCL635 is a potentially first-in-class antibody for the non-hormonal treatment of moderate to severe vasomotor symptoms (VMS, including hot flashes) during menopause.
• Market potential: In the US, there are approximately 40 million women of menopausal age, 30% of whom experience moderate to severe VMS. The market for novel non-hormonal therapies is estimated to be over $2 billion USD.
• Differentiation: Unlike daily oral treatments, ABCL635 offers a monthly subcutaneous dosing regimen, which is preferred by many patients. Furthermore, due to its antibody nature, it is expected to be non-hepatotoxic and non-drowsy, as it does not antagonize NK1R receptors.
Status: Phase 1 dosing began in Q3 2025. It is designed as a monthly injectable, offering a more convenient alternative to existing daily oral treatments, data expected mid-2026.
Internal Programs ABCL575
ABCL575, an OX40L antagonist, targets the treatment of atopic dermatitis (AD) and aims for best-in-class status.
• Market: The atopic dermatitis market is valued at over USD 11 billion and is growing at more than 25% annually.
• Benefits: Based on preclinical data, a dosing interval of once every six months is targeted, which would represent a significant improvement over current therapies. It addresses multiple immune pathways simultaneously and could be an important alternative for patients who do not respond to standard therapies such as IL-13 inhibitors.
Status: Phase 1 dosing began in late 2025. It is engineered for a long half-life, potentially allowing for dosing only once every six months, data expected mid-2026.
Royalty Portfolio and Partnered Programs
In addition to its own development, AbCellera has a passive royalty portfolio:
• A total of 18 molecules have already reached the clinical phase.
• The average royalty rate is 3.2%.
• The portfolio is broadly diversified: 47% is in oncology, 21% in neurology, and 17% in immunology/inflammation.
• Two antibodies against COVID-19 (bamlanivimab and bebtelovimab) have already received emergency use authorizations and have been marketed.
In December 2025, AbCellera secured a major new royalty source outside of drug sales:
Partner: Bruker Corporation.
Context: Settlement of a global patent litigation regarding “Beacon” optofluidic technology.
Terms: Bruker paid AbCellera $36 million upfront and agreed to pay ongoing royalties on the sale of its Beacon platform products for the life of the patents.
Significance: This provides a steady, predictable cash flow linked to laboratory equipment sales, diversifying AbCellera’s income.
Q3 2025
The Q3 2025 business update marks a significant turning point for AbCellera, as the company successfully advanced its first independently managed programs to clinical phases.
Clinical Advances and Pipeline Expansion
In clinical development, the company made significant progress by initiating Phase 1 clinical trials for two key programs: ABCL635 (initiated in June 2025) and ABCL575 (initiated in July 2025). With the nomination of ABCL688 as an additional development candidate for CTA-enabling studies, AbCellera is further expanding its autoimmune disease pipeline. To strengthen its clinical expertise, the company also appointed Dr. Sarah Noonberg as its first Chief Medical Officer (CMO) to strategically lead the advancement of its antibody-based therapeutics.
Infrastructure and Platform Investments
AbCellera successfully completed its planned platform investments in the first half of 2025. In parallel, operational activities commenced at the new clinical manufacturing site, strengthening the company’s independence in the production of clinical investigational drugs.
Partner Portfolio and Market Dynamics
The partner-initiated portfolio continues to grow steadily, reaching a cumulative 103 program launches in the third quarter of 2025. The number of molecules in clinical trials increased to a total of 18, with two programs now under the direct management of AbCellera, while 16 remain under partner leadership.
Financial Key Figures
The financial position as of September 30, 2025, is as follows:
• Available Liquidity: AbCellera has approximately $680 million in total available liquidity, consisting of approximately $520 million in cash and marketable securities, and approximately $160 million in government funding commitments.
• Revenue Performance: Third-quarter revenue increased to $8.8 million (compared to $6.3 million in the prior-year quarter), primarily driven by research fees and licensing.
• Net Loss: The company reported a net loss of $57.1 million, or $0.19 per share.
• Operating Expenses: Operating expenses of $80 million reflect increased investments in research and development ($55 million), while sales and administrative expenses remained largely stable.
Conclusion
AbCellera has evolved into a clinical-stage biotech company with a robust internal pipeline, while leveraging the advantages of its extensive partner network. The combination of strong liquidity, validated technology platforms, and pending clinical data positions the company for significant future growth. While royalty income from partner programs provides long-term security, the greatest leverage for value creation lies in the successful development of its proprietary candidates, ABCL635 and ABCL575. With approximately $680 million in available liquidity, management states this is sufficient to fund operations "well beyond the next 3 years.”
A short term catalyst could be the J.P. Morgan Healthcare Conference (Jan 14, 2026): Management is scheduled to present in a few days. The market is speculating on a new major "multi-target" partnership announcement or positive updates on the clinical pipeline.
At the moment I can’t really say if I would open up a position. On the one hand, it’s compelling, on the other the company is difficult to value.
What do you think about AbCellera? Is the stock a potential tenbagger?
Disclaimer
The content and materials presented or linked to are for informational and educational purposes only and do not constitute financial advice or recommendations and should not be considered as such.